ArticleSaudi journal of biological sciences2019
Anti-CD47 antibody eliminates bone tumors in rats.
Article in Saudi journal of biological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Article
- Tolerating CD47.Clinical and translational medicine · 2024Review
- Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.Frontiers in immunology · 2022Review
- Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone tumor is a rare heterogeneous malignancy. Osteosarcoma is the most common bone tumor with no apparent underlying pathogenesis, and its peak incidence often occurs during puberty. The intensive application of chemotherapy rarely alters the poor prognosis of the patients in advanced stage. Despite intensive chemotherapy in clinical practice, patients still suffer from the poor prognosis, or even progression of bone tumor. We identified integrin-associated protein (IAP) Cluster of Differentiation 47 (CD47) as a target for monoclonal antibody, and use anti-CD47 antibody to block its expression in bone tumors. CD47 was highly expressed in the bone tumor rats when comparing to the healthy rats. Likewise, Western blotting assay revealed a higher protein expression of CD47 in the bone tumor cells when compared to the normal osteoblasts. Further studies have shown the association between the mRNA expression of CD47 and the disordered bone tumors development and decreased rate of overall survival of diseased rats. In addition, blocking the CD47 monoclonal antibody has been shown to drive macrophages to engulf bone tumor cells in vitro and thus inhibiting tumor metastasis in rats. Taken together, the results of this study suggested that CD47 is a key regulator of bone tumor cell metastasis and that targeting inhibition of anti-CD47 may be a new immunotherapy for bone tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.